Evidence map›Paper›PMID 41519802›Full record

ArticleJournal of cheminformatics2026

Empowering federated learning for robust compound-protein interaction prediction across heterogeneous cross-pharma domains.

Takuto Koyama, Hiroaki Iwata, Ryosuke Kojima, Takao Otsuka, Aki Hasegawa, Seungeon Lee, Hiroshi Ueda, Toshiharu Morimoto, Ryoko Sasaki, Nao Torimoto and 5 more

Abstract read
In one paragraph

Article in Journal of cheminformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Takuto KoyamaGraduate School of Medicine, Kyoto University, Kyoto, Japan.
Hiroaki IwataFaculty of Medicine, Tottori University, Yonago, Japan.
Ryosuke KojimaGraduate School of Medicine, Kyoto University, Kyoto, Japan.
Takao OtsukaGraduate School of Medicine, Kyoto University, Kyoto, Japan.
Aki HasegawaGraduate School of Medicine, Kyoto University, Kyoto, Japan.
Seungeon LeeGraduate School of Medicine, Kyoto University, Kyoto, Japan.
Hiroshi UedaPharmaceutical Research Laboratories, Toray Industries, Inc., Kamakura, Japan.
Toshiharu MorimotoTokyo New Drug Research Laboratories, Kowa Co., Ltd., Higashimurayama, Japan.
Ryoko SasakiKyowa Kirin Co., Ltd., Machida, Japan.
Nao TorimotoResearch Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan.
Sei MurakamiPharmaceuticals Research Laboratories, Sanwa Kagaku Kenkyusho Co., Ltd., Inabe, Japan.
Manabu TojoPharmaceutical Discovery Research Laboratories, Teijin Pharma Limited, Hino, Japan.
Teruki HonmaRIKEN Center for Biosystems Dynamics Research, Yokohama, Japan.
Shigeyuki MatsumotoGraduate School of Medicine, Kyoto University, Kyoto, Japan. matsumoto.shigeyuki.4z@kyoto-u.ac.jp.
Yasushi OkunoGraduate School of Medicine, Kyoto University, Kyoto, Japan. okuno.yasushi.4c@kyoto-u.ac.jp.

Funding

Japan Agency for Medical Research and Development JP24nk0101111h010Japan Agency for Medical Research and Development JP24nk0101111h0105Japan Society for the Promotion of Science JP24KJ1510
6 · The paper itself

Abstract

Accurately predicting novel compound-protein interactions (CPIs) is essential for accelerating drug discovery. The generalizability of machine learning-based CPI prediction models relies significantly on the availability and diversity of CPI datasets. To maximize data utility, particularly for highly confidential datasets maintained by industries, federated learning (FL)-which integrates multi-site data while preserving privacy-has emerged as a promising approach. Nonetheless, its effectiveness when applied to heterogeneous data from diverse molecular domains, a common real-world scenario, remains unclear, thereby limiting its broader adoption. This study evaluates FL for CPI prediction using datasets spanning multiple chemical and protein domains, providing practical guidance for optimizing the FL approach. Results indicate that the FL model enhanced out-of-domain prediction performance but was surpassed by local models for in-domain data under data heterogeneity. Drawing on these findings, a new strategy was developed to achieve robust performance for in- and out-of-domain tasks: a similarity-guided ensemble (SGE) that combines the global FL model with fine-tuned models based on each client's local data. This method demonstrated effectiveness with real-world industry data, including samples from the public database and 13 pharmaceutical companies. Cumulatively, these findings offer practical guidance for implementing FL in contemporary drug discovery processes. SCIENTIFIC CONTRIBUTION: This study identifies the performance trade-offs caused by heterogeneous data distributions in FL for CPI prediction. To overcome these challenges, we developed a workflow integrating local fine-tuning and a SGE, ensuring robust accuracy for both in-domain and out-of-domain predictions. The effectiveness of this approach was validated using both public datasets and real-world in-house datasets from 13 pharmaceutical companies.

Indexed as

Compound-protein interactionFederated learning

Identifiers

PMID41519802
PMCPMC12879444

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.